Merck and Japanese start-up launch collaboration
Both companies to accelerate development and manufacturing of viral vector-based gene therapy applications
15-Dec-2022 -
Merck has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation. Both companies aim to integrate their capabilities to provide streamlined development, manufacturing and testing for ...
adeno-associated virus vectors
gene therapies
viral vectors